Health care and Internet companies are expected to have some of the strongest third-quarter profit gains in the IBD 50. The consensus analyst estimates for medical leaders Gilead Sciences (GILD) and Lannett (LCI) exceed 200% growth. The June-quarter results would keep both companies on already-fast profit growth paths. Gilead made headlines Friday, when the U.S. Food & Drug Administration approved the company’s once-a-day pill for hepatitis C.